Journals / Turkish Journal of Anaesthesiology and Reanimation / 2016 / Cilt: 44 - Sayı: 6

Sıçanlarda Paklitaksel İlişkili Periferik Nöropatik Ağrı Üzerine Anakinra'nın Etkisi

The Effect of Anakinra on Paclitaxel-Induced Peripheral Neuropathic Pain in Rats

Pages
287–294
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Anakinra may be useful to reduce paclitaxel-induced neuropathic pain; further, 100 mg kg−1 anakinra may have greater analgesic and antioxidant activities.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Paclitaxel is used in the treatment of cancer, and it may cause interleukin-1 beta (IL-1β)-related peripheral neuropathic pain.
📊
Key Findings & Data:While our primary aim was to investigate the analgesic efficacy of an IL-1β antagonist, a secondary outcome was to assess whether a correlation exists between analgesic effects and antioxidant activity.
💡
Conclusion & Impact:Conclusion: Anakinra may be useful to reduce paclitaxel-induced neuropathic pain; further, 100 mg kg−1 anakinra may have greater analgesic and antioxidant activities.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Paclitaxel is used in the treatment of cancer, and it may cause interleukin-1 beta (IL-1β)-related peripheral neuropathic pain. While our primary aim was to investigate the analgesic efficacy of an IL-1β antagonist, a secondary outcome was to assess whether a correlation exists between analgesic effects and antioxidant activity. Methods: A total of 24 albino Wistar male rats were divided into the following groups: paclitaxel-control, paclitaxel+50 mg kg−1 anakinra, paclitaxel+100 mg kg−1 anakinra and healthy group (HG). After the normal paw pain threshold in all animal groups was measured using a Basile algesimeter, a single dose of 2 mg kg−1 paclitaxel was intraperitoneally administered on the 1st, 3rd, 5th and 7th days. Anakinra was intraperitoneally administered following the final paclitaxel administration. The paw pain thresholds in the groups were measured before and seven days after paclitaxel administration and at the 1st and 3rd hours after anakinra administration. After the third hour of measurement, the rats were killed with high doses of ketamine, and the paw tissues were removed. Malondialdehyde, myeloperoxidase and total glutathione levels were measured in claw tissues, and IL-1β gene expression was determined. The biochemical results were compared with the results of the HG; in the meanwhile the claw pain threshold results were compared with the results obtained after the last paclitaxel and the results obtained from the 1st and 3rd hours after the anakinra application. Results: The claw paw pain threshold of the rats decreased one and three hours after anakinra administration. Further, 100 mg kg−1 anakinra had greater analgesic activity than 50 mg kg−1 anakinra. A correlation was found between the antioxidant and analgesic activities of 100 mg kg−1 anakinra. Conclusion: Anakinra may be useful to reduce paclitaxel-induced neuropathic pain; further, 100 mg kg−1 anakinra may have greater analgesic and antioxidant activities.

Özet

Amaç: Paklitaksel kanser tedavisinde kullanılan ve IL-1 Beta ilişkili periferal nöropati meydana getirebilen bir ilaçtır. Primer amacımız Paklitaksel ilişkili periferal nöropatik ağrıda Anakin- ra'nın analjezik etkinliğini araştırmak iken bir diğer hedefimiz ise anakinranın analjezik etkinliği ile antioksidan aktivitesi arasında korelasyon olup olmadığını araştırmaktır. Yöntemler: Toplamda 24 Albino Wistar deney hayvanları, pak- litaksel uygulanan kontrol (PAC), paklitaksel+50 mg kg-1 ana- kinra (PAC-50), paklitaksel+100 mg kg-1 anakinra (PAC-100) ve herhangi bir işlem uygulanmayan sağlıklı gruplara (HG) ayrıldı. Tüm hayvan gruplarının normal pençe ağrı eşikleri Ba- sile Aljezimetre kullanılarak ölçüldükten sonra, sıçanların PAC, PAC-50 ve PAC-100 gruplarına paklitaksel 2 mg kg-1 tek doz 1, 3, 5, ve 7. günlerde intraperitoneal olarak toplam dört kez uygulandı. Son Paklitaksel dozundan sonra sıçanlara intraperi- toneal yoldan Anakinra verildi.Tüm sıçanların pençe ağrı eşik- leri son paklitaksel dozundan sonra ayrıca Anakinra verildikten 1 ve 3 saat sonra ölçüldü. Üçüncü saatteki ölçümden hemen sonra sıçanlar yüksek doz ketamin anestezisi ile öldürülerek ayak pençe dokuları çıkartıldı. Pençe dokularında malondial- dehit, myeloperoksidaz ve total glutatyon düzeyleri ölçüldü ve IL-1? gen ekspresyonu tayini yapıldı. Elde edilen biyokimyasal sonuçlar HG grubu ile; pençe ağrı eşikleri ise son paklitaksel dozu sonrası ile Anakinra 1. ve 3. saatler karşılaştırılarak de- ğerlendirildi. Bulgular: Elli ve 100 mg kg-1 anakinra uygulanan hayvanların ayak pençesinde ağrı eşiği birinci ve üçüncü saatlerde anlamlı düşüş gösterdi. Ayrıca anakinra uygulanan PAC-100 grubunun analjezik aktivitesi PAC-50 grubundan daha fazla saptandı. 100 mg kg-1 Anakinra'nın antioksidan ve analjezik aktiviteleri arasında korelasyon bulundu. Sonuç: Anakinra paklitaksele bağlı nöropatik ağrının azaltılma- sında yararlı olabilir. Ayrıca 100 mg kg-1 anakinra daha etkin anal- jezik ve antioksidan aktivite sağlayabilir

🔖

Cite This Article

KUYRUKLUYILDIZ, U., KÜPELİ, İ., BEDİR, Z., ÖZMEN, Ö., ONK, D., SÜLEYMAN, B., MAMMADOV, R., SÜLEYMAN, H. (2016). Sıçanlarda Paklitaksel İlişkili Periferik Nöropatik Ağrı Üzerine Anakinra'nın Etkisi. Turkish Journal of Anaesthesiology and Reanimation, Cilt: 44 - Sayı: 6, 287–294. https://ajindex.com/articles/370305

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. v1. Fuchs DA, Johnson RK. Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep 1978
  2. Boyette-Davis JA, Cata JP, Driver LC, Novy DM, Bruel BM, Mooring DL, et al. Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine. Cancer Chemother Pharmacol 2013
  3. [CrossRef] 3. Duggett NA, Griffiths LA, McKenna OE, de Santis V, Yongsanguanchai N, Mokori EB, et al. Oxidative stress in the development, maintenance and resolution of paclitaxel-induced painful neuropathy. Neuroscience 2016
  4. [CrossRef ] 4. Argyriou AA, Cavaletti G, Briani C, Velasco R, Bruna J, Campagnolo M, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity. Cancer 2013
  5. [CrossRef] 5. Kursun YZ, Yildiz F, Kaymaz Ö, Önal SA. Effects of presence of metastasis on pain treatment ın patients with cancer: a retrospective study. Turk J Anaesthesiol Reanim 2014
  6. [CrossRef] 6. Fishbain DA, Cole B, Lewis JE, Gao J, Rosomoff RS. Do Opioids Induce Hyperalgesia in Humans? An Evidence‐Based Structured Review. Pain Med 2009
  7. [CrossRef] 7. Kim HK, Park SK, Zhou JL, Taglialatela G, Chung K, Coggeshall RE, et al. Reactive oxygen species (ROS) play an important role in a rat model of neuropathic pain. Pain 2004
  8. [CrossRef] 8. Vallejo R, Tilley DM, Vogel L, Benyamin R. The role of glia and the immune system in the development and maintenance of neuropathic pain. Pain Practice 2010
  9. [CrossRef ] 9. Boyette-Davis J, Xin W, Zhang H, Dougherty P. Intraepidermal nerve fiber loss corresponds to the development of Taxol-induced hyperalgesia and can be prevented by treatment with minocycline. Pain 2011
  10. [CrossRef] 10. Peters CM, Jimenez-Andrade JM, Kuskowski MA, Ghilardi JR, Mantyh PW. An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Res 2007
  11. [CrossRef] 11. Bsibsi M, Ravid R, Gveric D, van Noort JM. Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 2002
  12. [CrossRef] 12. Watkins LR, Maier SF. Glia: a novel drug discovery target for clinical pain. Nat Rev Drug Discov 2003
  13. [CrossRef ] 13. Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue wi